SIRT With Tremelimumab and Durvalumab for Resectable HCC
Not yet recruiting
AstraZeneca
Phase 1
2023-05-01
The goal of this research study is to evaluate the safety and tolerability of tremelimumab
and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in
participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery.
The names of the interventions involved in this study are:
- Durvalumab (a type of immunotherapy)
- Tremelimumab (a type of immunotherapy)
- Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere
bead)
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Not yet recruiting
Sirtex Medical
Phase 1
2023-05-01
The goal of this research study is to evaluate the safety and tolerability of tremelimumab
and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in
participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery.
The names of the interventions involved in this study are:
- Durvalumab (a type of immunotherapy)
- Tremelimumab (a type of immunotherapy)
- Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere
bead)
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Not yet recruiting
Jiping Wang, MD, PhD
Phase 1
2023-05-01
The goal of this research study is to evaluate the safety and tolerability of tremelimumab
and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in
participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery.
The names of the interventions involved in this study are:
- Durvalumab (a type of immunotherapy)
- Tremelimumab (a type of immunotherapy)
- Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere
bead)
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
